1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 4: 
Controls—visual analysis results for GMCa
ModelsAll Lobes (%)
NonepileptogenicUnclearArtifactsCorrected Specificity (Excluding Artifacts and Nonepileptogenic)
T114.553.222.646.8
T1+T221.045.217.754.8
T1+FLAIR16.150.019.450.0
T1+T2+FLAIR16.148.425.851.6
  • ↵a Visual interpretation results for GMC analysis for controls are presented. Results contain the percentage of controls scored by the reviewer as nonepileptogenic, unclear, and artifacts. Finally, corrected specificity is reported as the percentage of controls that did not have unclear findings—that is, all findings identified as artifacts/nonepileptogenic lesions and patients with no findings (VBM specificity prior to visual analysis).